Corbus Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $61.90. The company has a market capitalization of $82.70 million, a price-to-earnings ratio of -1.45 and a beta ...
William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened today at $7.10. Effectively assess a stock's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback